Heart analysis during DOTATOC PET/CT for neuroendocrine tumors
Part of Heart & circulation clinical trials.
This study looks at how a PET/CT scan (called gallium-68 DOTATOC) can also check your heart health while scanning for a neuroendocrine tumor. It aims to see if the routine scan can give extra information about your heart function without any extra visits or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your doctor has ordered a special type of PET/CT scan (called gallium-68 DOTATOC) to check for a neuroendocrine tumor.
- You do not have a history of heart disease or a severe irregular heartbeat.
- You are not currently taking a somatostatin analog (a medicine that can affect the scan).
- You do not have severe kidney disease, Cushing's syndrome, or a known allergy to the scan tracer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This study uses a PET/CT scan with a small amount of radioactive tracer to see how neuroendocrine tumors are behaving in adults. It may help doctors better detect and evaluate these tumors, especially when symptoms suggest a carcinoid-type hormone problem.
This trial tests a new PET scan tracer to find neuroendocrine tumors in the body. It may help doctors see where the tumors are and plan better treatment.
This study tests a special PET scan called 68Ga-DOTATOC to see if it can find certain breast cancer cells in the body. It may help doctors better understand your cancer, especially if it has spread to the liver or bones.
This trial tests a special PET scan to better evaluate gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It may help your doctor see where the tumors are in your body.
This study tests an imaging scan using a special tracer (68Ga-HA-DOTATATE) to look for tumors that have somatostatin receptors. It may help doctors better locate suspected tumor sites so treatment planning can be more accurate.
Hear when a new Cardiac Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.